Research ArticleSpecial Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems
Drug Metabolites as Cytochrome P450 Inhibitors: A Retrospective Analysis and Proposed Algorithm for Evaluation of the Pharmacokinetic Interaction Potential of Metabolites in Drug Discovery and Development
Ernesto Callegari, Amit S. Kalgutkar, Louis Leung, R. Scott Obach, David R. Plowchalk and Susanna Tse
Drug Metabolism and Disposition December 2013, 41 (12) 2047-2055; DOI: https://doi.org/10.1124/dmd.113.052241
Ernesto Callegari
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities (E.C., L.L., R.S.O., S.T.) and Clinical Pharmacology (D.R.P.), Pfizer Inc., Groton, Connecticut; and Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Pfizer Inc., Cambridge, Massachusetts (A.S.K.)
Amit S. Kalgutkar
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities (E.C., L.L., R.S.O., S.T.) and Clinical Pharmacology (D.R.P.), Pfizer Inc., Groton, Connecticut; and Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Pfizer Inc., Cambridge, Massachusetts (A.S.K.)
Louis Leung
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities (E.C., L.L., R.S.O., S.T.) and Clinical Pharmacology (D.R.P.), Pfizer Inc., Groton, Connecticut; and Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Pfizer Inc., Cambridge, Massachusetts (A.S.K.)
R. Scott Obach
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities (E.C., L.L., R.S.O., S.T.) and Clinical Pharmacology (D.R.P.), Pfizer Inc., Groton, Connecticut; and Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Pfizer Inc., Cambridge, Massachusetts (A.S.K.)
David R. Plowchalk
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities (E.C., L.L., R.S.O., S.T.) and Clinical Pharmacology (D.R.P.), Pfizer Inc., Groton, Connecticut; and Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Pfizer Inc., Cambridge, Massachusetts (A.S.K.)
Susanna Tse
Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities (E.C., L.L., R.S.O., S.T.) and Clinical Pharmacology (D.R.P.), Pfizer Inc., Groton, Connecticut; and Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Pfizer Inc., Cambridge, Massachusetts (A.S.K.)

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleSpecial Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems
Drug Metabolites as Cytochrome P450 Inhibitors
Ernesto Callegari, Amit S. Kalgutkar, Louis Leung, R. Scott Obach, David R. Plowchalk and Susanna Tse
Drug Metabolism and Disposition December 1, 2013, 41 (12) 2047-2055; DOI: https://doi.org/10.1124/dmd.113.052241
Research ArticleSpecial Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems
Drug Metabolites as Cytochrome P450 Inhibitors
Ernesto Callegari, Amit S. Kalgutkar, Louis Leung, R. Scott Obach, David R. Plowchalk and Susanna Tse
Drug Metabolism and Disposition December 1, 2013, 41 (12) 2047-2055; DOI: https://doi.org/10.1124/dmd.113.052241
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement